

#13  
7/17/99

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Hanna *et al.*

Appl. No. 09/030,832

Filed: February 26, 1998

For: **GABA<sub>A</sub> Receptor Epsilon  
Subunits**



Art Unit: 1645

Examiner: Hayes, R.

Atty. Docket: 1488.0950001/EKS/KKV

**Reply To Restriction Requirement**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In reply to the Office Action dated **December 8, 1999**, requesting an election of one invention to prosecute in the above-referenced patent application, Applicants hereby provisionally elect to prosecute the invention of Group II, represented by claims 95-147. This election is made without prejudice to or disclaimer of the other claims or inventions disclosed.

This election is made **with** traverse.

The Examiner has restricted the claims into the following groups:

- I. Claims 27-94 & 148-157, drawn to isolated nucleic acids that encode ET2 polypeptides, vectors and host cells comprising such, as well as methods of producing the polypeptide.
- II. Claims 95-147, drawn to isolated nucleic acids that encode GABRE polypeptides, vectors and host cells comprising such, as well as methods of producing the polypeptide.
- III. Claim 10, drawn to purified ET2 polypeptides.

Applicants respectfully traverse the restriction requirement. It is the Examiner's position that the three groups are directed to physically and functionally distinct products. Further, the Examiner stated that the "products can be prepared from different processes" and that the "polynucleotides of Group I are distinguished from the polynucleotides of Group II because they encode distinct proteins, as illustrated by their unique SEQ ID NOs" (Office action, pages 2 and 3). The Examiner further asserted that, due to the separate status in the art of the subject matter categorized into each group, the search and examination of the three groups together would constitute an undue burden.

The Examiner's basis for the restriction has been noted. However, even when patentably distinct inventions appear in a single application, restriction is improper unless the examiner can show that the search and examination of both groups would entail a "serious burden." *See* MPEP § 803. The Examiner has failed to make such a showing in the present instance.

Applicants submit that a search of the nucleic acid claims of Group I would clearly provide useful information for the polypeptide claim of Group III. This is because the genetic code is known. Moreover, in many, if not most, publications where a published nucleotide sequence is an open reading frame, the authors also include, as a matter of routine, the deduced amino acid sequence. Thus, the searches for nucleic acid molecules and polypeptides encoded by these molecules would clearly be overlapping.

Accordingly, Applicants request that the Examiner reconsider and withdraw the restriction requirement as applied to Groups I and III.

Regarding the restriction between Groups I and II and II and III, Applicants assert that again, there is no serious burden for the Examiner to overcome in order to examine all three groups. The ET2 polypeptide and the GABRE polypeptide are related polypeptides. Thus, a

search of the elected Group II (directed to GABRE) would lend itself to a search of Group I and of Group III (for the reasons set forth above) (directed to ET2).

Accordingly, Applicants request that the Examiner reconsider and withdraw the restriction requirement as applied to Groups I and II and Groups II and III.


Regarding the processes of preparing the products, Applicants submit that the fact that the products can be prepared from different processes does not sufficiently distinguish the three groups. The products therein can be made by the same process as well. The hypothetical methods of producing the products, as posed by the examiner on pages 2-3 of the Office action, will not affect the search for the products themselves.

Reconsideration and withdrawal of the Restriction Requirement, and consideration and allowance of all pending claims, are respectfully requested.

It is not believed that extensions of time are required, beyond those that may otherwise be provided for in accompanying documents. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor are hereby authorized to be charged to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Kristin K. Vidovich  
Attorney for Applicants  
Registration No. 41,448

Date: Jan. 10, 2000  
1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600

P:\USERS\kvidovic\1488\0950001\restriction.reply

Grau 1645

**STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.**

ATTORNEYS AT LAW

1100 NEW YORK AVENUE, N.W., SUITE 600

WASHINGTON, D.C. 20005-3934

(202) 371-2600

FACSIMILE: (202) 371-2540; (202) 371-6566

ROBERT GREENE STERNE  
EDWARD J. KESSLER  
JORGE A. GOLDSTEIN  
SAMUEL L. FOX  
DAVID K.S. CORNWELL  
ROBERT W. ESMOND  
TRACY-GENE G. DURKIN  
MICHELE A. CIMBALA  
MICHAEL B. RAY  
ROBERT E. SOKOHL  
ERIC K. STEFFE  
MICHAEL O. LEE

STEVEN R. LUDWIG  
JOHN M. COVERT\*  
LINDA E. ALCORN  
RAZ E. FLESHNER  
ROBERT C. MILLONIG  
MICHAEL V. MESSINGER  
JUDITH U. KIM  
TIMOTHY J. SHEA, JR.  
DONALD R. MCPHAIL  
PATRICK E. GARRETT  
STEPHEN G. WHITESIDE  
JEFFREY T. HELVEY\*

HEIDI L. KRAUS  
JEFFREY R. KURIN  
RAYMOND MILLIEN  
PATRICK D. O'BRIEN  
LAWRENCE B. BUGAISKY  
CRYSTAL D. SAYLES\*  
EDWARD W. YEE  
ALBERT L. FERRO\*  
DONALD R. BANOWIT  
PETER A. JACKMAN  
MOLLY A. MCCALL

TERESA U. MEDLER  
JEFFREY S. WEAVER  
KRISTIN K. VIDOVICH  
KENDRICK P. PATTERSON  
DONALD J. FEATHERSTONE  
GRANT E. REED  
VINCENT L. CAPUANO  
JOHN A. HARROUN\*  
MATTHEW M. CATLETT\*  
NATHAN K. KELLEY\*  
ALBERT J. FASULO II \*

KAREN R. MARKOWICZ\*\*  
SUZANNE E. ZISKA\*\*  
BRIAN J. DEL BUONO\*\*  
ANDREA J. KAMAGE\*\*  
NANCY J. LEITH\*\*  
TARJA H. NAUKKARINEN\*\*

\*BAR OTHER THAN D.C.

\*\*REGISTERED PATENT AGENTS



January 10, 2000

WRITER'S DIRECT NUMBER:  
(202) 789-5519

INTERNET ADDRESS:  
KVIDOVIC@SKGF.COM

Assistant Commissioner for Patents  
Washington, D.C. 20231

Re: U.S. Utility Patent Application  
Appl. No. 09/030,832; Filed: February 26, 1998  
For: **GABA<sub>A</sub> Receptor Epsilon Subunits**  
Inventors: Hanna *et al.*  
Our Ref: 1488.0950001/EKS/KKV

**RECEIVED**

JAN 11 2000

TECH CENTER 1800/2900

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Reply To Restriction Requirement; and
2. One (1) Return Postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Assistant Commissioner for Patents  
January 10, 2000  
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

*Kristin K. Vidovich*

Kristin K. Vidovich  
Attorney for Applicants  
Registration No. 41,448



EKS/KKV:asl  
Enclosures

P:\USERS\kvidovic\1488\0950001\restriction.reply.ptocov  
SKGF Rev. 9/23/98 dcw

**RECEIVED**  
JAN 11 2000  
TECH CENTER 1600/2900